1. Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease
- Author
-
Oskar Hansson, Michael W. Nagle, Julie Lee, Anders Mälarstig, Craig L. Hyde, Shorena Janelidze, Tarek A. Samad, Lori Fitz, Swetha Vijayaraghavan, Christopher D. Whelan, Erik Stomrud, Niklas Mattsson, Gayathri Ramaswamy, and Richard A. Margolin
- Subjects
Oncology ,Male ,Proteomics ,medicine.medical_specialty ,Neurology ,Amyloid beta ,Inflammation ,Apoptosis ,lcsh:RC346-429 ,Pathology and Forensic Medicine ,Cohort Studies ,Cellular and Molecular Neuroscience ,Alzheimer Disease ,Internal medicine ,medicine ,Dementia ,Humans ,ALCAM ,lcsh:Neurology. Diseases of the nervous system ,Aged ,Immunoassay ,Amyloid beta-Peptides ,biology ,business.industry ,Research ,Neurodegeneration ,Mild cognitive impairment ,Biomarker ,Middle Aged ,medicine.disease ,Blood proteins ,biology.protein ,Biomarker (medicine) ,Female ,Neurology (clinical) ,Angiogenesis ,medicine.symptom ,business ,Alzheimer’s disease - Abstract
To date, the development of disease-modifying therapies for Alzheimer’s disease (AD) has largely focused on the removal of amyloid beta Aβ fragments from the CNS. Proteomic profiling of patient fluids may help identify novel therapeutic targets and biomarkers associated with AD pathology. Here, we applied the Olink™ ProSeek immunoassay to measure 270 CSF and plasma proteins across 415 Aβ- negative cognitively normal individuals (Aβ- CN), 142 Aβ-positive CN (Aβ+ CN), 50 Aβ- mild cognitive impairment (MCI) patients, 75 Aβ+ MCI patients, and 161 Aβ+ AD patients from the Swedish BioFINDER study. A validation cohort included 59 Aβ- CN, 23 Aβ- + CN, 44 Aβ- MCI and 53 Aβ+ MCI. To compare protein concentrations in patients versus controls, we applied multiple linear regressions adjusting for age, gender, medications, smoking and mean subject-level protein concentration, and corrected findings for false discovery rate (FDR, q d q d q q
- Published
- 2019